Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion

被引：0
|
作者：
C Stavropoulou
C Sambani
H Rigana
V N Georgakakos
G Voutsinas
K N Manola
G E Pantelias
V Makropoulos
机构：
[1] Laboratory of Health Physics and Environmental Health,Department of Occupational and Industrial Hygiene
[2] NCSR ‘Demokritos’,undefined
[3] Laboratory of Environmental Mutagenesis and Carcinogenesis,undefined
[4] NCSR ‘Demokritos’,undefined
[5] National School of Public Health,undefined
[6] Athens,undefined
[7] Greece. E-mail: csambani@ipta.demokritos.gr,undefined
来源：
Leukemia | 2008年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1643 / 1646
页数：3
相关论文
共 50 条
  • [1] Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion
    Stavropoulou, C.
    Sambani, C.
    Rigana, H.
    Georgakakos, V. N.
    Voutsinas, G.
    Manola, K. N.
    Pantelias, G. E.
    Makropoulos, V.
    LEUKEMIA, 2008, 22 (08) : 1643 - 1646
  • [2] Glutathione-S-Transferase M1 Null Genotype in Autoimmune Hepatitis
    Naomi K. Fukagawa
    Ping Liang
    Muyao Li
    Takamaru Ashikaga
    K. Rajender Reddy
    Edward L. Krawitt
    Digestive Diseases and Sciences, 2001, 46 : 2080 - 2083
  • [3] Glutathione-S-transferase M1 null genotype in autoimmune hepatitis
    Fukagawa, NK
    Liang, P
    Li, MY
    Ashikaga, T
    Reddy, KR
    Krawitt, EL
    DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (10) : 2080 - 2083
  • [4] Glutathione S-transferase T1-null genotype interacts synergistically with heavy smoking on lung cancer risk
    Hou, SM
    Fält, S
    Nyberg, F
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2001, 38 (01) : 83 - 86
  • [5] Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion
    Giagounidis, AAN
    Haase, S
    Germing, U
    Heinsch, M
    Aul, C
    ACTA HAEMATOLOGICA, 2005, 113 (02) : 146 - 149
  • [6] Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
    Omar A. Alkharabsheh
    Salwa S. Saadeh
    Darci L. Zblewski
    Naseema Gangat
    Kebede H. Begna
    Michelle A. Elliott
    Hassan B. Alkhateeb
    Mrinal S. Patnaik
    William J. Hogan
    Mark R. Litzow
    Aref Al-Kali
    Annals of Hematology, 2019, 98 : 331 - 337
  • [7] Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
    Alkharabsheh, Omar A.
    Saadeh, Salwa S.
    Zblewski, Darci L.
    Gangat, Naseema
    Begna, Kebede H.
    Elliott, Michelle A.
    Alkhateeb, Hassan B.
    Patnaik, Mrinal S.
    Hogan, William J.
    Litzow, Mark R.
    Al-Kali, Aref
    ANNALS OF HEMATOLOGY, 2019, 98 (02) : 331 - 337
  • [8] Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
    Duong, Vu H.
    Komrokji, Rami S.
    List, Alan F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (02) : 105 - 116
  • [9] COMPARATIVE STUDY OF CONVENTIONAL CYTOGENETICS AND FISH FOR EGR1 IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROME AND 5Q DELETION
    Stavropoulou, C.
    Georgakakos, V.
    Manola, K.
    Pantelias, G.
    Sambani, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 411 - 411
  • [10] HETEROGENEITY IN CYTOGENETIC AND CLINICAL FEATURES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q
    Papaioannou, G.
    Athanasiadou, A.
    Gavriilaki, E.
    Bousiou, Z.
    Iskas, M.
    Papathanasiou, M.
    Stavroyianni, N.
    Sakellari, I.
    Anagnostopoulos, A.
    HAEMATOLOGICA, 2016, 101 : 505 - 505
12345